BCR-ABLm RNA在慢性粒细胞白血病患者分期及预后评估中的临床价值

Clinical value of BCR-ABL mRNA in staging and prognostic evaluation of patients with chronic myeloid leukemia

目的:探讨BCR-ABL mRNA表达在慢性粒细胞白血病(CML)患者分期及预后评估中的临床价值。方法:回顾性分析2016年11月至2018年10月本院收治的60例CML患者的临床资料,对比不同分期、不同危险度(Sokal预后评分)及治疗后不同时间段CML患者BCR-ABL mRNA表达情况。结果:BCR-ABL mRNA表达水平随着病情进展(慢性期<加速期<急变期)和危险度增加(低危者<中危者<高危者)均逐渐升高,随着治疗时间延长逐渐下降,治疗6、9、12个月时患者BCR-ABL mRNA表达水平均低于治疗前,差异有统计学意义(P<0.05)。结论:BCR-ABL mRNA检测在判断CML患者分期,评估疾病预后和疗效中具有一定临床应用价值。

Objective:To explore clinical value of BCR-ABL mRNA in staging and prognostic evaluation of patients with chronic myeloid leukemia(CML).Methods:The clinical data of 60 CML patients in Institute of Hematology of Puyang People’s Hospital from November 2016 to October 2019 were retrospectively analyzed.The expressions of BCR-ABL mRNA in the CML patients with different stages,different risks(Sokal prognostic score)and different time periods after the treatment were compared.Results:The expression levels of BCR-ABL mRNA gradually increased with the progression of the disease(chronic phase<accelerated phase<blast phase)and increased risk(low risk<intermediate risk<high risk),and gradually decreased with the prolonged treatment time.The expressions of BCR-ABL mRNA 6,9,and 12 months after the treatment were higher than that that before the treatment,and the differences were statistically significant(P<0.05).Conclusions:CR-ABL mRNA detection has certain clinical application value in judging the stage of the CML patients and evaluating the prognosis of the disease and the treatment efficacy.